prostate cancer

MUMBAI, India & NAPLES, Fla., June 26, 2026 Lupin Limited announced that it has received tentative approval from the...

BASEL, Switzerland, June 12, 2026 Roche announced that the U.S. Food and Drug Administration (FDA) has approved the VENTANA...

MELBOURNE, Australia & INDIANAPOLIS, U.S., June 2, 2026 Telix Pharmaceuticals announced positive Part 1 data from its global Phase...

BOSTON, June 1, 2026 Foundation Medicine announced that the U.S. Food and Drug Administration (FDA) has approved both FoundationOne®...

SILICON VALLEY, Calif. & BEIJING, June 1, 2026 Haisco Pharmaceutical Group Co., Ltd. has announced a landmark licensing and...

PARIS, France, June 1, 2026 Curium, a global leader in radiopharmaceuticals and nuclear medicine, has announced a strategic investment...

Latham, New York | May 28, 2026 AngioDynamics announced that Palmetto GBA has issued a final Local Coverage Determination...

SALT LAKE CITY, May 26, 2026 Myriad Genetics announced the launch of Prolaris® + AI, the first prostate cancer...

North Chicago, Ill., USA – May 21, 2026 AbbVie announced new oncology research findings ahead of the 2026 American...

SOUTH SAN FRANCISCO, California, 21 May 2026 Veracyte, Inc. announced that major Phase III clinical trial results involving its...